Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis

Schizophrenia Bulletin

Volumn 41, Issue 5, 2015, Pages 1171-1182

  Colizzi, Marco ^a,b   Iyegbe, Conrad ^b   Powell, John ^b   Ursini, Gianluca ^a,c   Porcelli, Annamaria ^a   Bonvino, Aurora ^a   Taurisano, Paolo ^a   Romano, Raffaella ^a   Masellis, Rita ^a   Blasi, Giuseppe ^a   Morgan, Craig ^b   Aitchison, Katherine ^b   Mondelli, Valeria ^b   Luzi, Sonija ^b   Kolliakou, Anna ^d   David, Anthony ^b   Murray, Robin M ^b   Bertolino, Alessandro ^a,e   Di Forti, Marta ^b  

^a UNIVERSITY OF BARI   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d King s College London   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Dopamine receptors type 2; G x E interaction; Schizophrenia; Schizotypy; Working memory

Indexed keywords

ACCURACY; ADULT; AGED; ALLELE; ARTICLE; CANNABIS EXPERIENCE QUESTIONNAIRE; CANNABIS USE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRD2 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RECEPTOR GENE; SCHIZOTYPAL PERSONALITY QUESTIONNAIRE; SIGNAL TRANSDUCTION; WORKING MEMORY; ADOLESCENT; CASE CONTROL STUDY; DISEASE PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MIDDLE AGED; PHYSIOLOGY; RISK; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SHORT TERM MEMORY; YOUNG ADULT;

CANNABIS; DOPAMINE 2 RECEPTOR; DRD2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; CANNABIS; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GENE-ENVIRONMENT INTERACTION; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2; RISK; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; YOUNG ADULT;

EID: 84941679831     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv032     Document Type: Article

References (68)

1. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res. 1999;33:543-548.
2. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008;34:1066-1082.
3. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468:203-212.
4. Tost H, Meyer-Lindenberg A. Puzzling over schizophrenia: schizophrenia, social environment and the brain. Nat Med. 2012;18:211-213.
5. Di Forti M, Murray RM. Cannabis consumption and risk of developing schizophrenia: myth or reality? Epidemiol Psichiatr Soc. 2005;14:184-187.
6. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8:885-895.
7. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31:608-612.
8. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
9. Fridberg DJ, Vollmer JM, O'Donnell BF, Skosnik PD. Cannabis users differ from non-users on measures of personality and schizotypy. Psychiatry Res. 2011;186:46-52.
10. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
11. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57:688-691.
12. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58:909-915.
13. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59:1337-1343.
14. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287:1123-1131.
15. Colizzi M, Fazio L, Ferranti L, et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related behavior. Neuropsychopharmacology. 2015;40:640-649.
16. Jockers-Scherübl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1054-1063.
17. Sevy S, Burdick KE, Visweswaraiah H, et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res. 2007;92:74-84.
18. Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, et al. Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med. 2008;38:1257-1266.
19. Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl). 2009;205:45-52.
20. Ferraro L, Russo M, O'Connor J, et al. Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res. 2013;150:129-135.
21. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259:413-431.
22. DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry. 2008;21:140-150.
23. Kumra S. Schizophrenia and cannabis use. Minn Med. 2007;90:36-38.
24. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21:152-162.
25. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549-562.
26. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20.
27. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677-1687.
28. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl). 2002;161:331-339.
29. French ED. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett. 1997;226:159-162.
30. Egerton A, Chaddock CA, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultrahigh risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74:106-112.
31. Murray RM, Mehta M, Di Forti M. Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol Psychiatry. 2014;75:430-431.
32. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293.
33. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 1998;42:211-221.
34. Rolls ET, Loh M, Deco G, Winterer G. Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat Rev Neurosci. 2008;9:696-709.
35. Ripke S, Neale BM, Corvin A, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421-427.
36. Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E. Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Mol Psychiatry. 2000;5:270-274.
37. Bertolino A, Fazio L, Caforio G, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain. 2009;132:417-425.
38. Usiello A, Baik JH, Rougé-Pont F, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408:199-203.
39. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA. 2007;104:20552-20557.
40. Bertolino A, Taurisano P, Pisciotta NM, et al. Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One. 2010;5:e9348.
41. Blasi G, Lo Bianco L, Taurisano P, et al. Functional variation of the dopamine D2 receptor gene is associated with emotional control as well as brain activity and connectivity during emotion processing in humans. J Neurosci. 2009;29:14812-14819.
42. Blasi G, Napolitano F, Ursini G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA. 2011;108:1158-1163.
43. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-491.
44. World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry (SCAN). Geneva, Switzerland: World Health Organization; 1992.
45. Bebbington PE, Nayani T. The Psychosis Screening Questionnaire. Int J Methods Psychiatr Res. 1995;5:11-19.
46. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012;72:811-816.
47. Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40:1509-1517.
48. Mallett R, Leff J, Bhugra D, Pang D, Zhao JH. Social environment, ethnicity and schizophrenia. A case-control study. Soc Psychiatry Psychiatr Epidemiol. 2002;37:329-335.
49. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
50. Blasi G, De Virgilio C, Papazacharias A, et al. Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry. 2013;70:921-930.
51. Chan AW, Pristach EA, Welte JW, Russell M. Use of the TWEAK test in screening for alcoholism/heavy drinking in three populations. Alcohol Clin Exp Res. 1993;17:1188-1192.
52. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull. 1991;17:555-564.
53. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57:1117-1127.
54. van Winkel R; Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68:148-157.
55. van Winkel R, van Beveren NJ, Simons C; Genetic Risk and Outcome of Psychosis (GROUP) Investigators. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology. 2011;36:2529-2537.
56. Verdejo-García A, Fagundo AB, Cuenca A, et al. COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology. 2013;38:1598-1606.
57. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31:2748-2757.
58. Costas J, Sanjuán J, Ramos-Ríos R, et al. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr Res. 2011;127:22-27.
59. Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry. 2011;199:380-385.
60. Drago J, Padungchaichot P, Accili D, Fuchs S. Dopamine receptors and dopamine transporter in brain function and addictive behaviors: insights from targeted mouse mutants. Dev Neurosci. 1998;20:188-203.
61. Self DW, Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 1998;51:49-60.
62. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology. 2004;47(Suppl 1):3-13.
63. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry. 2014;75:470-478.
64. Taurisano P, Romano R, Mancini M, et al. Prefronto-striatal physiology is associated with schizotypy and is modulated by a functional variant of DRD2. Front Behav Neurosci. 2014;8:235.
65. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol. 1994;103:171-183.
66. Barnes JJ, Dean AJ, Nandam LS, O'Connell RG, Bellgrove MA. The molecular genetics of executive function: role of monoamine system genes. Biol Psychiatry. 2011;69:e127-e143.
67. D'Esposito M, Zarahn E, Aguirre GK. Event-related functional MRI: implications for cognitive psychology. Psychol Bull. 1999;125:155-164.
68. Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry. 2011;168:1041-1049.